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Abstract. – NSAIDs are generally consid-
ered to be safe and well tolerated, but, even with
the advent of selective COX-2 inhibitors, nephro-
toxicity remains a concern. An impaired renal per-
fusion caused by the inhibition of prostaglandin
synthesis is claimed like the more frequent cause
of an acute renal failure due to NSAIDs, while a
chronic interstitial nephritis or an analgesic
nephropathy are believed the causes of a chronic
renal failure. The real incidence of renal side ef-
fects of NSAIDs is still unclear and it differs be-
tween the age of the patients and the reports pre-
sent in the literature. The occurrence of renal side
effects following prenatal exposure to NSAIDs
seems to be rare considering the large number of
pregnant woman treated with indomethacin or
other prostaglandin inhibitors. NSAID-related
nephrotoxicity remains an important clinical prob-
lem in the newborns, in whom the functionally im-
mature kidney may exert a significant effect on
the disposition of the drugs. Instead, nephrotoxic-
ity is a rare event in children and the risk is lower
than adults. In healthy adult patients the inci-
dence of renal adverse effects is very low, less
than 1%. The risk increased with age. The elderly
are at higher risk, and it is correlated at the pres-
ence of pretreatment renal disease, hypovolemia
due to use of diuretics, diabetes, congestive heart
failure or alteration of NSAID pharmacokinetics.
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Introduction
Nonsteroidal anti-inflammatory drugs
(NSAIDs) are the most widely used drugs in
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medicine and their use has dramatically in-
creased in recent years. NSAIDs are the most
commonly used class of medications for the
treatment of pain and inflammation, with an esti-
mated usage of over 30 million people per day.
NSAIDs often are administered during preg-
nancy and in newborns too. Particularly in-
domethacin, have been used for many years as
tocolytic agents to prevent premature uterine
contractions and to treat polyhydramnios. In very
low birth weight (VLBW) neonates, low-dose
prophylactic indomethacin significantly lowers
the incidence and severity of intraventricular he-
morrhage (IVH). For many years, indomethacin
has been the drug of choice for the treatment1
and prophylaxis of patent ductus arteriosus
(PDA) in preterm infants.
NSAIDs are generally considered to be safe
and well tolerated, but current studies indicate
that these pharmacological agents account for
7% of reported cases of acute renal failure and
35% of drug-induced acute renal failure in the
general population2. This review discusses the
available literature data concerning NSAID-relat-
ed nephrotoxicity, in the foetus, newborn, child,
and adult, with special emphasis on its clinical
aspects.
Pathophysiology of NSAID-induced
Nephrotoxicity
Prostaglandins are biologically active lipids
derived from the 20-carbon essential fatty acids,
acting as modulators and mediators in a large
spectrum of physiological processes and patho-
physiological conditions3. In addition to their
role in inflammation, prostaglandins regulate a
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variety of renal functions such as vascular tone,
salt and water balance, and renin release4.
COX-1 is constitutively expressed in several
tissues and is thought to participate in “house-
keeping” functions. In the kidney, it has been lo-
calized to mesangial cells, arteriolar smooth
muscle and endothelial cells, parietal epithelial
cells of Bowman’s capsule, and cortical and
medullary collecting ducts. This COX isoform
controls homeostatic functions such as regulating
renal blood flow5.
COX-2 is undetectable in most tissues but is
induced by a variety of stimuli and is associated
with inflammation. Constitutive expression of
COX-2 has been reported in certain tissues in-
cluding the kidneys5. Indeed, COX-2 mRNA and
immunoreactive protein are present at detectable
levels in normal adult mammalian kidney, name-
ly in macula densa (MD) cells and in scattered
cells in the cortical thick ascending limb cells
immediately adjacent to the MD6. In human kid-
ney, COX-2 expression has been reported to be
present in podocytes and arteriolar smooth mus-
cle cells7. COX-2 expression is also abundant in
the lipid-laden medullary interstitial cells in the
inner medulla and papilla. Some investigators
have reported that COX-2 may also be expressed
in inner medullary collecting duct cells or inter-
calated cells in the renal cortex8. Nevertheless,
constitutively expressed COX-1 is clearly the
most abundant isoform in the collecting duct, so
the physiological significance of COX-2 coex-
pression in these cells remains unclear. More-
over, a recent report has suggested that, in human
kidney, there is significant COX-2 expression in
the medullary vasa recta7.
COX-2 seems to be involved in the regula-
tion of glomerular haemodynamics, and has
been demonstrated to play a major role in
nephrogenesis8. 
Slater et al9 studied the expression of the 2
COX isoforms in human foetal membranes
throughout pregnancy and reported that an up-
regulation of COX-2, rather than COX-1, medi-
ates increased prostaglandin synthesis within the
foetal membranes before and during term and
preterm labour. These considerations have led
some investigators to use selective COX-2 in-
hibitors in the management of preterm labour:
nimesulide, which may be free of adverse effects
caused by COX-1 inhibition, has been suggested
as a potential tocolytic agent10.
Prostaglandins are actively synthesised within
the kidney and interact with a family of distinct
receptors that are expressed in highly restricted
regions along the nephron and exert important
regulatory effects on renal function11.
In humans, the importance of renal
prostaglandins becomes evident during treatment
with NSAIDs, which inhibit the COX enzyme
and block prostaglandin synthesis. There is a
reasonably good correlation between the poten-
cy of these drugs as cyclooxygenase inhibitors
and their anti-inflammatory activity12. NSAID
treatment may precipitate renal failure in sus-
ceptible individuals and cause severe, albeit
rare, complications in infants exposed to
NSAIDs in utero13. Four PGE2 receptor sub-
types (EP1, EP2, EP3, and EP4) have been
cloned and characterised and present different
properties. For example, the renal EP1 receptors
may contribute to the natriuretic and diuretic ac-
tions of PGE2 and may be present in glomerular
mesangial cells, where it could have a role as
vasoconstrictor14. EP2 receptors exhibit only
low levels of expression in the kidney, but may
have an important role in protecting systemic
blood pressure, perhaps via its vasodilator
effect15. All prostanoid receptors act in concert
as physiological buffers to protect the kidney
from excessive functional changes during peri-
ods of physiological stress, and the loss of the
combined effects of these receptors may con-
tribute to the adverse effects seen with NSAID
administration. Therefore, selective prostanoid
receptor antagonists may provide new therapeu-
tic approaches for the management of NSAID-
induced adverse renal effects16.
Evidences and Information Sources
Effects of NSAIDs on renal function were ex-
amined in published literature indexed by
PubMed from 1980 to August 2010, in order to
identify English language literature concerning
acute renal failure in foetus, newborn, child and
adult under NSAID’s therapy. The available liter-
ature data were reviewed with special emphasis
on their clinical aspects.
Using electronic database, we looked for suit-
able multicentric and prospective randomized
controlled trials (RCT), comparative studies, re-
views, case series, case reports, on humans and
animals. The terms and text words (and their
combinations and truncated synonyms) were
adapted as appropriate to search by combining
the terms NSAIDs AND nephrotoxicity, or and
renal failure, both and newborn or child or adult.
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indomethacin developed transient renal insuffi-
ciency25. 
More recently, Van der Heijden et al26 reported
that 6 neonates exposed to indomethacin in utero
for at least 5 weeks died of anuria. Pomeranz et
al27 described transient acute renal failure in a
pair of twins delivered at 34 weeks’ whose moth-
er had received indomethacin in the last two
weeks for premature contractions. Finally, a sig-
nificantly higher frequency of oliguria was ob-
served, in the first 24 hours of life, in babies born
at less than 30 weeks’ gestation whose mothers
had been exposed to indomethacin for preterm
labour, compared with babies exposed to placebo
in utero28.
A summary of renal adverse effects occurring
after prenatal exposure of some NSAIDs is pre-
sented in Table I.
NSAID Exposure in Neonatal Period
Patent ductus arteriosus (PDA) is a very im-
portant pathology in the neonatal period by an
epidemiologic, clinic and therapeutic point of
view. Physiopathology has been extensively re-
view very recently29. Treatment of PDA with
NSAIDs, through the inhibition of prostaglandin
synthesis, is indicated before left to right ductal
shunting occurs30 and a recent 3rd Cochrane re-
view has been dedicated to this argument31.
Benitz32 very recently greatly criticised contem-
porary terapeutic approach.
However, during the neonatal period, this type
of therapy may itself cause adverse effects such
as oliguria, gastrointestinal haemorrhage, renal
failure, decrease of cerebral blood flow, and in-
crease of serum creatinine levels.
For many years, indomethacin has been the
drug of choice in the treatment1 and prophylax-
is33 of PDA in premature neonates. However,
adverse effects such as transient or permanent
alterations in renal function34, necrotising ente-
rocolitis19, gastrointestinal haemorrhage34, and
impairment of cerebral blood flow35 have been
frequently observed even at low doses (0,2
mg/kg). Reduction of urinary volume and
glomerular filtration rate are usually reversible
within 48 hours after discontinuation of thera-
py, although oliguria may persist for 2 weeks36.
Strategies to minimise the adverse renal effects
associated with indomethacin, such as the use
of prolonged low doses of this drug, or the co-
administration of indomethacin and other phar-
macological agents (furosemide or dopamine),
have not been successful37. Other NSAIDs have
State of the Art
Nephrotoxicity During the Prenatal Period
NSAIDs, like all drugs, should be used with
care during pregnancy. Yet NSAIDs, particularly
indomethacin, have been used for many years as
tocolytic agents to prevent premature uterine
contractions and to treat polyhydramnios. How-
ever, the use of these drugs has been associated
with constriction of foetal ductus arteriosus with
severe consequences. The proportion of foetuses
developing ductal constriction after indomethacin
exposure increases with advancing of gestational
age, with 100% experiencing constriction at >34
weeks’ gestation17. However, this effect is usually
reversible when the drug is stopped. The underly-
ing mechanisms leading to renal dysfunction in
the foetus are probably the same as those in post-
natal and adult life. 
The major adverse effects associated with
NSAID prenatal exposure are oligohydramnios,
fatal anuria, renal failure, intracranial haemor-
rhage, necrotising enterocolitis, patent ductus ar-
teriosus (PDA), oliguria, augmentation of serum
creatinine levels and metabolic acidosis.
The occurrence of renal complications fol-
lowing prenatal exposure to NSAIDs seems to
be rare considering the large number of preg-
nant women treated with indomethacin or other
prostaglandin inhibitors18. Up to the present
day, several cases of severe and sometimes irre-
versible renal insufficiency have been described
in human neonates exposed to indomethacin
during fetal life, as discussed below. In a case-
control study, 57 babies exposed prenatally to
indomethacin, born at or before 30 weeks’ ges-
tation, had an increased incidence of intracra-
nial hemorrhage, necrotising enterocolitis and
PDA19. A reduction in urine output and a mod-
erate increase in serum creatinine levels were
also observed during the first three days of life
in these neonates. A similar study reported that
babies born at less than 31 weeks’ gestation had
an increased incidence of periventricular haem-
orrhage, PDA and renal function impairment
when they were delivered within 48 hours of
their last in utero exposure to indomethacin20.
Itskovitz et al21, described the occurrence of
oligohydramnios, neonatal anuria and perinatal
death in 3 neonates after 1 week’s in utero ex-
posure to indomethacin. Other Authors ob-
served 3 cases of fatal anuria in foetuses after
some weeks of indomethacin therapy22-24. Five
of 23 neonates born after prenatal exposure to
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also been used to treat PDA in preterm infants
but have been shown to be associated with ad-
verse effects, as in the case of sulindac and
mefenamic acid38 or to be less effective than in-
domethacin at closing the duct, as in the case of
acetylsalicylic acid39.
Relatively few studies have evaluated ibupro-
fen therapy in preterm infants with PDA. The
results of these investigations have demonstrat-
ed that ibuprofen, compared with in-
domethacin, is effective at closing the duct and
is associated with fewer cerebral33 and renal ad-
verse effects40. Recently its prophylactic use,
although not yet uniformly accepted, has been
advocated. In a phase I trial, Vargarigou et al41,
observed that the administration to 34 prema-
ture neonates of one dose of ibuprofen lysine
(10 mg/kg intravenously) within 3 hours after
birth, followed by 5 mg/kg per dose intra-
venously at 24 and 48 hours of age, reduced the
incidence of PDA and the severity of the respi-
ratory status without affecting renal function.
In a prospective randomised study, Van Over-
meire et al42 compared the effectiveness and ad-
verse effects of intravenous ibuprofen (an ini-
tial dose of 10 mg/kg followed by 5 mg/kg 24
and 48 hours later)  and intravenous in-
domethacin (3×0.2 mg/kg at 12-hour intervals),
starting on the third day of life, in the treatment
of PDA in preterm infants with acute respirato-
ry distress syndrome (ARDS). Ibuprofen was as
effective as indomethacin in closing the ductus
without decreasing urinary output or increasing
serum creatinine levels. NSAID-related nephro-
toxicity in the newborn may result from the
mechanism of action of these drugs combined
with renal immaturity. By blunting the effect of
prostaglandins on the afferent arteriole,
NSAIDs can impair glomerular filtration rate in
both the foetus and the newborn.
Three different hypothesis have been advocat-
ed to explain the difference in renal side effects
between indomethacin and ibuprofen: (1) one
possibility is that both drugs inhibit the cy-
clooxygenase isozymes to different extents in the
neonatal kidney; (2) the different pharmacokinet-
ic characteristics result in different potentials to
impair renal function; (3) the possibility of non-
prostaglandin effects.
Very recently we described longterm effects of
NSAIDs on renal function and renal volume,
namely in extremly low birth weight (ELBW)43.
NSAID-induced Nephrotoxicity in Children
Renal failure has been reported to be a rare
event in children exposed to NSAIDs and is usu-
ally reversible after discontinuation of the drug44.
Children may be at great risk of nephrotoxicity in
some conditions like dehydration accompanying
fever, the most common paediatric indication for
NSAID treatment45.
Adverse effects associated with NSAID use in
children are renal failure, metabolic acidosis,
hypocalcemia, acute flank pain and interstitial
nephritis46-49.
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N° of individual studied
Author exposed to the drug Drug Renal adverse effect
Norton ME, et al19 57 Indomethacin Oliguria, ↑ serum creatinine
levels 
Souter D, et al20 39 Indomethacin ↑ serum creatinine levels
Panter KR, et al28 19 Indomethacin Oliguria
vs Placebo
Itskovitz J, et al21 3 Indomethacin Oligohydramnion, fatal anuria
Jacqz-Aigrin E, et al25 23 Indomethacin Renal failure ( in 5 subjects)
Van der Heijden BJ, et al26 6 Indomethacin Fatal anuria (in all 6 subjects)
Kaplan BS, et al13 6 Indomethacin- Renal failure
Ibuprofen
Table I. Summary of renal adverse effects occurring after prenatal exposure of some anti-inflammatory drugs (NSAIDs).
In a clinical trial involving 119 febrile chil-
dren, increases in blood urea nitrogen (BUN), al-
though not statistically significant, were ob-
served after administration of a single dose of
ibuprofen (5 to 10 mg/kg), but no increase in cre-
atinine levels was observed either for ibuprofen
or paracetamol (acetaminophen) recipients50. In a
randomised trial involving 83,915 children51,
55,785 of whom were treated with ibuprofen for
fever, no renal impairment was observed. More-
over, the risk of renal failure was not increased
following short-term use of ibuprofen compared
to paracetamol. Another study concerning the
same population45 showed that the risk of less se-
vere renal impairment, in the 795 of 83,915 pa-
tients who required hospitalisation, was small
and not significantly greater for ibuprofen than
for paracetamol. The prevalences of BUN levels
greater than 18 mg/dl and creatinine levels higher
than 0.7 mg/dl were slightly higher in the 108
children with a concomitant diagnosis of dehy-
dration, both in ibuprofen-treated subjects and
paracetamol-treated subjects. Finally, caution
should be taken when NSAIDs are administered
to individuals with underlying renal disorders or
in association with other potentially nephrotoxic
drugs. Moghal et al52 reported renal impairment
of varying degrees following ibuprofen treatment
in 3 children with intravascular volume depletion
and/or pre-existing renal problems. On the other
hand, transient renal failure was reported53 in
children with cystic fibrosis receiving aminogly-
cosides and ibuprofen simultaneously.
A summary of renal adverse effects of
NSAIDs after administration in children is pre-
sented in Table II.
NSAID-induced Nephrotoxicity in Adults
In addition to various side effects, both acute
and chronic renal failures have been observed in
patients treated with non-specific and specific
COX-2 inhibitors54,55. NSAID-induced nephro-
toxicity includes acute renal failure due to
haemodynamic changes in the kidney, tuboloint-
erstitial nephritis, glomerular lesions, reduced
sodium and water excretion, hyperkaliemia and
hypertension54,56,57.
Renal adverse effects elicited by NSAIDs are
dose-dependent58. In healthy adult patients the in-
cidence of renal adverse effects is very low
(<1%). However, the elderly are at higher risk.
Indeed, the latter may present age-related decline
in glomerular filtration rate, hypovolemia due to
use of loop diuretics, diabetes, congestive heart
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Author N° of individual studied Drug Renal adverse effect
Van Biljoun46 1 Ibuprofen ARF + Oedema
McIntire et al44 2 Ibuprofen, Non oliguric ARF + acute 
flurbiprofen flank pain
Kim et al49 1 Ibuprofen ARF
Kelly et al50 3 Ibuprofen Renal impairment of varyng
degrees
Kovesi et al53 4 (Cystic fibrosis) Ibuprofen ARF
Simckes et al48 1 (Sickle cell disease) Ketoprofen Irreversible ARF
Becker-Cohen R and 1 (Juvenile rheumatoid Naproxen Intestitial nephritis-ARF
Frishberg Y85 arthritis)
Ulinski et al86 7 Ketoprofene, ARF
Ibuprofen
Schaller S, Kaplan BS47 4 Unspecified Non oliguric ARF
NSAID
Krause et al87 7 Unspecified ARF + acute flank pain +
NSAID abdominal pain +
vomiting
Fletcher et al88 3 Vioxx ARF
Table II. Summary of renal adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in children.
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failure (CHF), cirrhosis or nephrosis59, morbid
conditions leading to worsening of renal function
or alteration of NSAID pharmacokinetics (higher
free drug levels, higher concentration of drug,
slowed hepatic metabolism of drug)57.
Moreover, the elderly frequently presents hy-
pertension treated with antihypertensive drugs in-
cluding β-blockers, ACE–inhibitors or diuretics.
NSAIDs alter the effect of these antihypertensive
drugs, eliciting an impairment of controlled hy-
pertension, particularly in patients treated with
ACE-inhibitors60.
Furthermore, evidence has been provided that
both diclofenac and indomethacin induce signif-
icant decreases in glomerular filtration rate
(GFR), urine flow, excretion rates of sodium
and potassium, osmolality clearance and free
water clearance in CHF patients treated with
ACE-inhibitors61. The presence of renal disease
might represent a contra-indication to NSAIDs
use. Whelton et al62 reported how almost 30%
of patients with renal disease have a relevant
risk of worsening renal function when exposed
to non-selective NSAIDs. However, the effects
of NSAIDs on progression of chronic kidney
disease need to be better clarified. A recent
Canadian study performed in an elderly com-
munity – based cohort63 demonstrated that pa-
tients treated with high dose of NSAID con-
sumption presented an increased risk for rapid
chronic kidney disease progression (26% in-
creased risk for decreased in estimated GFR).
No differential risk was to be found between
non-selective and selective NSAID users. For
this reason neither non-selective nor selective
COX-2 inhibitors should be administered to pa-
tients with chronic renal disease. Two case-
control studies carried out to identify the risk
of renal adverse effects in elderly patients have
been published58-64. Griffin et al58 report a rele-
vant increased risk of acute renal failure (58%)
in current NSAID users. The risk of intrinsic
renal failure is present only in patients with
chronic renal failure, while the risk of pre-renal
failure is independent from the presence of
chronic renal disease. Ibuprofen, indomethacin,
piroxicam, ketoprofen, fenoprofen would seem
to present a high risk of renal failure (odds ra-
tio >1.5) which increases on a par with drug
dosage. On the contrary, naproxen and
nonaspirin salicylates would seem to present a
low risk (odds ratio <1) seemingly not correlat-
ed to the dose employed. Diclofenac and sulin-
dac would seem to present an intermediate risk
(Odd’s ratio 1.40 and 1.47 respectively). The
contemporary use of two or more NSAIDs ex-
poses patients to the highest risk of renal failure
(Odd’s ratio 3.35)58. 
A study conducted on a general population
aged between 50 to 84 years in the United
Kingdom64 reported a 3-fold greater risk of de-
veloping a first-ever diagnosis of clinical ARF
in NSAID users compared to non-NSAID users.
Meloxicam, more selective for COX-2 than tra-
ditional NSAIDs, features a higher risk com-
pared to diclofenac and naproxen. The contem-
porary use of cardiovascular drugs and NSAIDs
and diuretics or calcium channel blockers ex-
poses patients to a greater risk (relative risk
11.6 and 7.8 respectively). Long term NSAID
therapy together with high drug doses elicits a
slight increase in this risk. On commencing
NSAID treatment, no increased risk of ARF
was observed. These results are in contrast with
the above-mentioned study58, although the actu-
al reasons underlying these differences are not
clear. As stated by the Authors, the characteris-
tics of the populations investigated in the two
studies may have differed. In fact, in the study
performed by Griffin et al58 the patients were
older and all hospitalized. It might be argued
that the incidence of renal adverse effects pro-
duced by non-selective NSAIDs is age-depen-
dent and closely related to renal perfusion. Ac-
cordingly, use of these drugs should be avoided
in the elderly and in patients affected by heart
failure, hypertension, diabetes and chronic renal
disease. The use of NSAIDs for topical applica-
tion is generally considered to be safe because
of the marginal percutaneous absorption (5-
8%)65. Nevertheless, several cases of acute renal
failure have been reported following topical
NSAID treatment. In particular, we found three
case reports of acute renal failure manifested af-
ter the use of ketoprofen, ibuprofen and piroxi-
cam, respectively65-67. The mechanism of these
events has not been well established, likely be-
ing elicited via an allergic mechanism. 
To clarify the actual renal safety profile of
COX-2 inhibitors, Zhang et al.68 carried out a
meta-analysis on 114 informative reports focus-
ing on celecoxib, rofecoxib, valdecoxib, parecox-
ib, etoricoxib and lumiracoxib. The study showed
a significant heterogeneity regarding renal events
produced by various agents, exhibiting no class
effect of COX-2 inhibitors. These findings are of
extreme importance in view of the fact that previ-
ous studies had supported the presence of a class
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effect. Furthermore, following these findings the
physician was given greater liberty in prescribing
coxib treatment best suited to clinical conditions
of patients. Rofecoxib significantly increased the
risk of composite renal events (relative risk 1.53),
including significantly elevated risks for periph-
eral oedema, hypertension and renal dysfunction
(relative risk 1.43, 1.55, and 2.31, respectively).
The use of higher doses and longer treatment du-
ration increased the renal risk associated with ro-
fecoxib. Valdecoxib and parecoxib are consid-
ered to increase the rate of renal adverse effects
(relative risk 1.24). No other COX-2 inhibitors
significantly increased the risk of renal adverse
effects (relative risk 1.05 and 1.07 for etoricoxib
and lumiracoxib, respectively). Celecoxib was
associated with reduced rates of composite renal
dysfunction (relative risk 0.97), hypertension and
renal dysfunction (relative risk 0.83 and 0.61, re-
spectively). The limits imposed by this meta-
analysis cannot be extended to investigate the im-
pact of patient comorbidity with conditions such
as underlying chronic renal failure, on the safety
of coxib administration. Secondly, additional
studies should be performed to assess the actual
safety profile of etoricoxib and lumiracoxib, in
view of the scarce number of trials performed to
date to this regard.
The elderly presents a higher risk of acute re-
nal failure following coxib treatment than
younger subjects, in agreement to findings ob-
served with non-selective NSAIDs69. Indeed,
coxibs are not indicated for use in patients with
cardiovascular and renal disease. Side effects
are manifested in correlation to the adminis-
tered dose; accordingly, the use of high doses of
COX-2 inhibitors in the elderly should be
avoided. Patients should be monitored regularly
in order to prevent the onset of side effects re-
lated to concomitant illness or new drug pre-
scriptions70. Blood pressure should be moni-
tored for all patients undergoing coxib therapy.
On registering a significant increase in blood
pressure, coxib treatment should be immediate-
ly withdrawn and substituted for another anal-
gesic and also an increase of blood pressure
should be treated immediately. The appropriate
dosage of COX-2 inhibitors in order to avoid re-
nal adverse effects has not yet been identified.
However, it is reasonable to maintain that daily
doses of rofecoxib 25 mg, celecoxib 200 mg
and etoricoxib 90 mg should not increase the
risk of renal failure either in healthy or elderly
patients. 
In recent years several published case reports
have revealed how renal adverse effects are also
associated with administration of COX-2 selec-
tive inhibitors71,72. Both celecoxib (200 mg /day)
and rofecoxib (25 mg/day) induced the onset of
acute interstitial nephritis. Management of these
cases consisted in immediate withdrawal of cox-
ib, although renal function was not completely
restored in all cases.
Although administration of NSAIDs for
chronic pain is strongly opposed by physicians,
these drugs are massively employed in the man-
agement of postoperative pain. The incidence of
postoperative renal failure related to NSAID use
is a very rare event and has not yet  been well es-
tablished, being estimated, however, in the range
of 0.001 to 0.1%73. A review published in 200773
investigated the effect of NSAIDs on postopera-
tive renal function in patients with normal preop-
erative function. The study included 23 trials in-
vestigating 1459 patients, resulting in the finding
of NSAID-induced slight, transient negative ef-
fects on kidney function in adults without previ-
ous renal disease. No cases of acute renal failure
or severe renal failure or severe renal impairment
were reported in the trials.
Finally, the use of NSAIDs for the treatment
of postoperative pain is considered to be safe, al-
though a few considerations should be made.
First, a marked difference is observed in the
incidence of renal adverse effects between chron-
ic surgical and non-surgical chronic patients.
Postoperative patients are likely better-assisted,
more careful attention being paid to prevent renal
hypoperfusion and maintaining adequate renal
blood flow. 
Second, renal adverse effects are not necessar-
ily related to the duration of NSAID administra-
tion, indeed, acute renal failure may occur even
after a few days of intake. 
The topics mentioned above are still object of
controversies. As stated by Myles and Power74 in
1998, “there needs to be continued research and
the most efficient method for answering these
questions are large, epidemiological case-control
or cohort studies”.  
Finally in the reference to pharmacological
prevention of NSAID-induced renal toxicity,
several Authors have proposed the use of nitric
oxide (i.e. arginine) donors75. Furthermore, oth-
er studies suggest oxidative phosphorilation by
the drug itself and an additional potential mech-
anism of overcoming NSAID-induced nephro-
toxicity75,76.
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Conclusions
Historically, clinical advances registered in the
nineteenth and twentieth centuries led to devel-
opment of NSAIDs77.
Nowadays NSAIDs represent the most widely
used drug in medical practice. Indeed, the use of
this class of compounds has increased dramati-
cally during the recent years among patients of
all ages, ranging from the newborn to the adults.
Their use during pregnancy has also increased, in
spite of the emerging findings: even short-term
administration of NSAIDs during the late preg-
nancy period is correlated with a significant in-
crease in risks of premature closure of ductus ar-
teriosus78.
It is very interesting to note that selective
COX-2 inhibitors, often prescribed during preg-
nancy, are capable of crossing into the placenta
although these compounds are not used in the
new born79. According to the opinion of the Au-
thor and to the current literature, ibuprofen
should represent the therapeutic option of choice
during the neonatal period because of its lower
nephrotoxic potential80.
On the basis of the specific mechanism in-
volved in the activation, NSAID nephrotoxicity
should be considered as significant adverse ef-
fect, in particular in high risk patients of all ages.
Similar to many of many other cases of drug-in-
duced renal damage, acute renal failure is often
initially non-oliguric. Thus, monitoring of renal
function  and serum creatinine levels is mandato-
ry during therapy, together with assessment of
electrolytes and blood pressure81. In particular, a
novel approach for early and sensitive detection
of NSAID- induced nephrotoxicity in newborns,
based on the monitoring of urinary PGE2, has
been successfully used82.
Other biomarkers of early glomerular (such as
cystatin C) or tubular damage will probably be-
come increasingly involved in the future83.
No effort should be spared in attempting to
prevent unnecessary administration of NSAIDs,
especially in high risk patients (Table III) such as
patients with hypovolemia and/or pre-existing re-
nal problems. These efforts should include the
choice of compounds having a lower nephrotoxic
potential, identification of the most appropriate
dosage, avoiding concomitant administration of
other nephrotoxic drugs, providing for early di-
agnosis of nephrotoxicity, and by limiting the du-
ration of the treatment. However, it should be un-
derlined how additional iatrogenic damage can
often be prevented through immediate interrup-
tion of the administration of the drug, consider-
ing largely reversibility of the nephrotoxicity in-
duced by the drug. 
Particular caution should be taken in the han-
dling of newly developed NSAIDs, particularly
off-label or unlicensed products.
Future research in this field should be under-
taken to focus on the actual role of NSAIDs in
clinical practice for each age group, concentrat-
ing particularly on pregnant women.
Over-the-counter analgesics are usually
deemed to be safe to use. However, patients us-
ing this type of medication without first consult-
ing their physician may not be aware of potential
hazards and predisposing factors aggravating ad-
verse effects. 
Ongoing medical education focusing on the
interaction of NSAIDs with other drugs in terms
of nephrotoxicity is mandatory84.
Lastly, additional medical information listing
the disadvantages and drawbacks of these drugs
should be made available, bearing in mind that
pharmakon means poison in ancient Greek.
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Perinatal age
• Multiple pregnancies (especially monochorionic twin
pregnancies)
• Prolonged and cumulative doses
• Short term between treatment and delivery
• Genetic factors
• Low birthweight
• Concomitant drugs (aminoglycosides, glycopeptides,
diuretics)
Pediatric age
• Dehydration
• Hypovolemia
• Haemorrhage
• Congestive heart failure
• Liver failure
• Pre-existing renal problems
• Urinary tract malformations
• Recurrent urinary tract infections
• NSAIDs multitherapy
• Concomitant drugs (beta-blockers, ACE inhibitors,
diuretics, aminoglycosides)
• Alcohol consumption
• Cystic fibrosis
Adult age
• Elderly
• Renal disease
• NSAIDs multitherapy
• Concomitant drugs (inotropes, calcium channel
blockers, diuretics)
• Prolonged therapy
Table III. Selected risk factors for NSAIDs-induced acute
nephrotoxicity.
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